Insider · CIK 0001488774
R. LaDuane Clifton
Files at ZVRA (ZEVRA THERAPEUTICS, INC.). First filing Feb 14, 2025, latest Feb 14, 2025.
In brief
R. LaDuane Clifton files SEC Form 4 as CFO at ZVRA (ZEVRA THERAPEUTICS, INC.). Since Feb 14, 2025, R. LaDuane Clifton has reported 0 open-market buys worth $0 and 1 open-market sell worth $86k, the latest filed on Feb 14, 2025.
A track record needs three past buys with six months of prices behind them; R. LaDuane Clifton has 0, so none is measured yet.
The newest scored trade: sold $86k of ZVRA on Feb 13, 2025, filed Feb 14, 2025, scored 16 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZVRA: ZEVRA THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 16Weak | ZEVRA THERAPEUTICS, INC. | $86k 11,000 shares | -18% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 16, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | 345,428 0.59% of outstanding | $3.4M | Mar 16, 2026 | $127k |
| Jan 30, 2026 | ZVRA ZEVRA THERAPEUTICS INC | 14,000 0.02% of outstanding | $124k | Jan 30, 2026 | none |
| Feb 13, 2025 | ZVRA ZEVRA THERAPEUTICS INC | 11,000 0.02% of outstanding | $85k | Feb 13, 2025 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Common Stock | +140,667 | $0.00 | $0 | 192,028 | Jan 7, 2026 |
| Dec 31, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | FTax withholding Common Stock | -48,513 | $8.96 | $435k | 143,515 | Jan 7, 2026 |
| Dec 31, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Restricted Stock Unitderivative | -86,667 | $0.00 | $0 | 0 | Jan 7, 2026 |
| Dec 31, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Restricted Stock Unitderivative | -34,000 | $0.00 | $0 | 0 | Jan 7, 2026 |
| Dec 31, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Performance Stock Unitderivative | -20,000 | $0.00 | $0 | 0 | Jan 7, 2026 |
| Feb 13, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -11,000 | $7.86 | $86k | 51,361 | Feb 14, 2025 |
| Jan 31, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Common Stock | +43,333 | - | - | 62,361 | Feb 3, 2025 |
| Jan 31, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | MOption exercise Restricted Stock Unitderivative | -43,333 | $0.00 | $0 | 86,667 | Feb 3, 2025 |
| Jan 30, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +68,000 | $0.00 | $0 | 68,000 | Feb 3, 2025 |
| Jan 30, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | AGrant or award Restricted Stock Unitderivative | +34,000 | $0.00 | $0 | 34,000 | Feb 3, 2025 |
Questions about R. LaDuane Clifton
Answered from the filings on this page, as of the latest one.
Is R. LaDuane Clifton buying or selling?
Not in the last 12 months. R. LaDuane Clifton's latest open-market trade on SEC Form 4 was sold $86k of ZVRA on Feb 13, 2025.
How did R. LaDuane Clifton's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and R. LaDuane Clifton has 0.
Where does R. LaDuane Clifton file Form 4?
R. LaDuane Clifton has filed Form 4 at ZVRA (ZEVRA THERAPEUTICS, INC.) as CFO & Treasurer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.